Sugi Predict

Sugi Predict / Compounds / SCHEMBL1785799

SCHEMBL1785799

SCHEMBL1785799

O=C1Cc2ccc([N+](=O)[O-])cc2C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP2 O95551 1/20 0.56
▸ LMNA P02545 2/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ MAPT P10636 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ TLR9 Q9NR96 1/20 0.54
▸ PNMT P11086 5/20 0.50
▸ ADRA2A P08913 3/20 0.50
▸ PTPRC P08575 1/20 0.47
▸ S100A4 P26447 1/20 0.47
▸ ADRA2B P18089 2/20 0.46
▸ ADRA2C P18825 2/20 0.46
▸ PARP1 P09874 1/20 0.46
▸ TSHR P16473 2/20 0.45
▸ HSP90AA1 P07900 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ CA12 O43570 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27905491 0.88 LMNA (0.62) TDP2LMNAMEN1KMT2AMAPT
SCHEMBL1098412 0.87 TDP2 (0.51) TDP2LMNAMEN1KMT2AMAPT
SCHEMBL1870205 0.87 PNMT (0.54) TDP2LMNAMEN1KMT2AMAPT
SCHEMBL10229556 0.84 TDP2 (0.49) TDP2LMNAMEN1KMT2AMAPT
SCHEMBL5145572 0.84 PNMT (0.51) TDP2LMNAMEN1KMT2AMAPT
SCHEMBL2616914 0.83 TDP2 (0.73) TDP2LMNAMEN1KMT2AMAPT
Phosphonic Acid SCHEMBL28853711 0.81 TLR9 (0.56) TDP2LMNAMEN1KMT2AMAPT
SCHEMBL30049268 0.79 TLR9 (0.79) TDP2LMNAMEN1KMT2AMAPT
SCHEMBL987760 0.79 TLR9 (0.79) TDP2LMNAMEN1KMT2AMAPT
SCHEMBL467503 0.78 PNMT (0.57) TDP2LMNAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441679-B2 Acrylamide-substituted indane compounds and therapeutic use thereof SANOFI (FR) 2025-10-14 — — US disclosed
CN-116057042-B Acrylamide-substituted indane compounds and their therapeutic uses 赛诺菲 2024-10-18 — — CN disclosed
EP-3661918-B1 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS RECURIUM IP HOLDINGS LLC (US) 2024-05-08 — — EP disclosed
US-20240050428-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-15 — — US disclosed
CN-111094253-B 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs 里科瑞尔姆IP控股有限责任公司 2023-08-29 — — CN disclosed
US-20230265047-A1 Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof SANOFI (FR) 2023-08-24 — — US disclosed
US-20230265047-A1 Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof SANOFI (FR) 2023-08-24 — — US disclosed
EP-4225749-A1 COMPOUNDS AND METHODS OF TREATING CANCERS Cullgen (Shanghai), Inc. (CN) 2023-08-16 — — EP disclosed
CN-116583509-A Compounds and methods for treating cancer 上海睿跃生物科技有限公司 2023-08-11 — — CN disclosed
EP-4188907-A1 ACRYLAMIDE-SUBSTITUTED INDANE COMPOUNDS AND THERAPEUTIC USE THEREOF SANOFI (FR) 2023-06-07 — — EP disclosed
US-6232260-B1 ORGANOMETALLIC COMPLEX COMPRISES A GROUP 3 TO 10 TRANSITION OR LANTHANIDE METAL, M, AND AT LEAST ONE INDENOINDOLYL LIGAND THAT IS .PI.-BONDED TO M. EQUISTAR CHEMICALS, L.P. 2001-05-15 — — US disclosed
WO-2001027125-A1 SINGLE-SITE CATALYSTS FOR OLEFIN POLYMERIZATION EQUISTAR CHEMICALS, L.P. (US) 2001-04-19 — — WO disclosed
EP-1091946-A1 NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE WIKSTRÖM, Hakan Vilhelm (NL) 2001-04-18 — — EP disclosed
US-6117898-A Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase ASTRA AKTIEBOLAG (SE) 2000-09-12 — — US disclosed
WO-2000001680-A1 NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE WIKSTROEM HAKAN VILHELM (NL) 2000-01-13 — — WO disclosed
EP-0759027-B1 BICYCLIC AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHETASE ASTRA AB (SE) 1999-08-04 — — EP disclosed
US-5807886-A Bicyclic amidine dervatives as inhibitors of nitric oxide synthetase ASTRA AKTIEBOLAG (SE) 1998-09-15 — — US disclosed
EP-0759027-A1 BICYCLIC AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHETASE Astra Aktiebolag (SE) 1997-02-26 — — EP disclosed
WO-1997006158-A1 BICYCLIC AMIDINE DERIVATIVES USEFUL IN THERAPY ASTRA AKTIEBOLAG (SE) 1997-02-20 — — WO disclosed
WO-1996001817-A1 BICYCLIC AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHETASE ASTRA AKTIEBOLAG (SE) 1996-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441679-B2 Acrylamide-substituted indane compounds and therapeutic use thereof IDH2, INA, IDH3A TDP2 1261/4885LMNA 1999/4885MEN1 2972/4885
US-20240050428-A1 COMPOUNDS AND METHODS OF TREATING CANCERS GSPT1, GGT1, VHL TDP2 890/4885LMNA 2400/4885MEN1 169/4885
US-20230265047-A1 Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof IDH2, INA, IDH3A TDP2 1261/4885LMNA 1999/4885MEN1 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.